MENVEO is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by Neisseria meningitidis serogroups A, C, W135 and Y.
Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website atwww.hpra.ie. Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255
Menveo is a registered trademark of the GlaxoSmithKline Group of Companies
JD. August 2019. PM-IE-MNV-WCNT-190002
Get in touch
To discuss our products, supply, educational events or any other information
Registered in Ireland: GlaxoSmithKline (Ireland) Limited, a private company limited by shares, and a member of the GlaxoSmithKline group of companies. Registered in Ireland with Company Number 15513. Registered office: 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.
GOL. Last Updated: January 2020. PM-IE-NA-WCNT-200002